Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureLetizia Matera
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
10.1200/jco.2017.73.7585
10.1200/jco.2017.73.7585
10.1200/jco.2017.75.6155
10.1200/jco.2017.75.6155
10.1056/nejmoa2114663
10.1056/nejmoa2114663
10.1056/nejmoa1903765
10.1056/nejmoa1903765
10.1056/nejmoa1911149
10.1056/nejmoa1911149
10.1056/nejmoa1607303
10.1056/nejmoa1607303
10.1056/nejmoa1810527
10.1056/nejmoa1810527
10.1038/s43018-024-00893-z
10.1038/s43018-024-00893-z
10.1146/annurev-med-070909-182917
10.1146/annurev-med-070909-182917
10.3390/ijms24054522
10.3390/ijms24054522
10.1016/j.ctrv.2024.102861
10.1016/j.ctrv.2024.102861
10.1007/s11427-021-2140-8
10.1007/s11427-021-2140-8
Randomized phase ii trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102
10.1200/jco.2017.76.9331 · 2018
10.1056/nejmoa1109653
10.1056/nejmoa1109653
10.1200/jco-24-02086
10.1200/jco-24-02086
10.1056/nejmoa1813904
10.1056/nejmoa1813904
10.1158/1557-3265.sabcs25-rf7-02
10.1158/1557-3265.sabcs25-rf7-02
10.1056/nejmoa2214131
10.1056/nejmoa2214131
10.1200/jco.22.00338
10.1200/jco.22.00338
10.1056/nejmoa2410858
10.1056/nejmoa2410858
10.1056/nejmoa1802905
10.1056/nejmoa1802905
10.1056/nejmoa1706450
10.1056/nejmoa1706450
10.1016/j.cell.2017.07.029
10.1016/j.cell.2017.07.029
10.3390/cells11162508
10.3390/cells11162508
10.4143/crt.2022.001
10.4143/crt.2022.001
10.1007/s10549-023-07010-1
10.1007/s10549-023-07010-1
10.1038/s41523-026-00968-3
10.1038/s41523-026-00968-3
10.1186/s13058-020-01320-8
10.1186/s13058-020-01320-8
10.1056/nejmoa2501796
10.1056/nejmoa2501796
10.1016/s1470-2045(24)00673-9
10.1016/s1470-2045(24)00673-9
10.1158/1078-0432.ccr-10-1694
10.1158/1078-0432.ccr-10-1694
10.1016/s1470-2045(17)30376-5
10.1016/s1470-2045(17)30376-5
10.1038/s41523-024-00648-0
10.1038/s41523-024-00648-0
VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor–Positive/HER2−/PIK3CA wild-type advanced breast cancer
10.1200/jco-25-02643 · 2026
10.1158/1078-0432.ccr-14-1306
10.1158/1078-0432.ccr-14-1306
10.1038/s41416-022-02025-9
10.1038/s41416-022-02025-9
10.1016/s1470-2045(24)00034-2
10.1016/s1470-2045(24)00034-2
10.1002/cpdd.615
10.1002/cpdd.615
10.1158/1078-0432.ccr-25-0992
10.1158/1078-0432.ccr-25-0992 · doi-reference
10.1001/jamanetworkopen.2024.61067
10.1001/jamanetworkopen.2024.61067 · doi-reference
PACE: a randomized phase ii study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor–positive/Human epidermal growth factor receptor–negative metastatic breast cancer
10.1200/jco.23.01940 · doi-reference
10.1200/jco-24-01865
10.1200/jco-24-01865 · doi-reference
10.3390/ijms26125844
10.3390/ijms26125844 · doi-reference
10.1126/scitranslmed.3005747
10.1126/scitranslmed.3005747 · doi-reference
10.15252/embj.201693929
10.15252/embj.201693929 · doi-reference
10.1200/jco.2026.44.17_suppl.lba1008
10.1200/jco.2026.44.17_suppl.lba1008 · doi-reference